NCT05790850

Brief Summary

The PRIMER (Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy) trial is a pilot designed to estimate the feasibility of integrating a home-based pre-operative exercise and mindfulness program (pre-habilitation program) for patients scheduled to undergo radical cystectomy for bladder cancer in an attempt to improve both physical and psychological conditioning pre-operatively.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
1mo left

Started Mar 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress98%
Mar 2023Jun 2026

First Submitted

Initial submission to the registry

March 16, 2023

Completed
14 days until next milestone

First Posted

Study publicly available on registry

March 30, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

March 30, 2023

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2025

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Expected
Last Updated

December 16, 2024

Status Verified

December 1, 2024

Enrollment Period

2.5 years

First QC Date

March 16, 2023

Last Update Submit

December 10, 2024

Conditions

Keywords

MindfulnessMeditationPhysical ExercisePre-habilitation

Outcome Measures

Primary Outcomes (2)

  • Number of patient-reported days devoted to solitary psychological support

    Patient-reported days devoted to self-directed solitary psychological support related to cancer treatment during a 30 day period pre-operatively in the pre-habilitation program group

    30 days

  • Number of patient-reported days devoted to exercise

    Patient-reported minutes per day devoted to high-intensity exercise during a 30 day period pre-operatively in the pre-habilitation program group

    30 days

Secondary Outcomes (5)

  • Post-operative complication rate

    30 days post-operatively

  • Patient-reported health-related quality of life as assessed by the European Organization for Research and Treatment of Cancer (EORTC) questionnaire.

    4-8 weeks pre-operatively, 2 weeks pre-operatively, 30 days post-operatively

  • Peak oxygen uptake as measured on cardiopulmonary exercise testing (CPET)

    4-8 weeks pre-operatively, 2 weeks pre-operatively, 30 days post-operatively

  • Dispositional mindfulness as assessed by the Mindfulness Awareness Attention Scale (MAAS)

    4-8 weeks pre-operatively, 2 weeks pre-operatively, 30 days post-operatively

  • Perceived stress as assessed by the Perceived Stress Scale 10 (PSS 10)

    4-8 weeks pre-operatively, 2 weeks pre-operatively, 30 days post-operatively

Study Arms (2)

Control

NO INTERVENTION

Usual preoperative care prior to radical cystectomy

Intervention

EXPERIMENTAL

Preoperative pre-habilitation

Behavioral: Pre-operative physical exerciseBehavioral: Pre-operative mindfulness meditation practice

Interventions

Virtual instructor-guided twice weekly cycling-based high-intensity aerobic exercise program for a total of 30 days. Participants will use a study provided recumbent exercise bike and wristband fitness tracker to exercise and log the number of days they exercise with an instructor and self-directed cycling.

Intervention

Daily self-directed mindfulness practice involving a guided imagery meditation for a total of 30 days. Participants will use a study provided guided-imagery meditation audio file loaded to a study provided wristband fitness tracker. Participants will log the number of days they listen to the audio file or participate in self-directed solitary psychological support.

Intervention

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥18 years of age
  • Good surgical candidate determined by treating surgeon
  • Histologically documented muscle invasive urothelial carcinoma of the bladder, high-risk non-muscle invasive bladder cancer, non-muscle invasive bladder cancer refractory to BCG, cisplatin ineligible muscle invasive bladder cancer receiving upfront cystectomy, urothelial carcinoma of the bladder with variant histology
  • Adequate Organ Function per protocol definition
  • ECOG performance status ≤2
  • Received medical clearance to complete cardiopulmonary exercise testing
  • Willing to use the personal or study provided devices for monitoring and performing the exercise routines.
  • Fluent in English or Spanish for the EORTC QLQ questionnaire
  • No known contraindications to high intensity exercise

You may not qualify if:

  • Contraindications to participating in aerobic exercise
  • Currently participating in an aerobic exercise program
  • New onset chest pain nor dyspnea with exertion
  • Histologically documented micropapillary or sarcomatoid bladder cancer
  • Distant metastatic carcinoma

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Virginia

Charlottesville, Virginia, 22903, United States

RECRUITING

MeSH Terms

Conditions

Urinary Bladder NeoplasmsNon-Muscle Invasive Bladder NeoplasmsMotor Activity

Condition Hierarchy (Ancestors)

Urologic NeoplasmsUrogenital NeoplasmsNeoplasms by SiteNeoplasmsFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrinary Bladder DiseasesUrologic DiseasesMale Urogenital DiseasesCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeBehavior

Central Study Contacts

Christine Ibilibor

CONTACT

Francesca Whitefield

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

March 16, 2023

First Posted

March 30, 2023

Study Start

March 30, 2023

Primary Completion

October 1, 2025

Study Completion (Estimated)

June 1, 2026

Last Updated

December 16, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will not share

Summary of trial outcome data through publication or grant reporting requirements.

Locations